Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Mo, Qianxing  [Clear All Filters]
2014
Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, Chen F, Roh TT, Lay E, Ho PLevy, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2014.
2016
Feng Z, Yao Y, Zhou C, Chen F, Wu F, Wei L, Liu W, Dong S, Redell M, Mo Q, et al. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. J Hematol Oncol. 2016;9(1):24.
2019
Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LAnn, Padron E, List AF, et al. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leuk Res. 2019;81:56-61.
2020
Horton TM, Hoff FW, van Dijk A, Jenkins GN, Morrison D, Bhatla T, Hogan L, Romanos-Sirakis E, Meyer J, Carroll WL, et al. The effects of sample handling on proteomics assessed by reverse phase protein arrays (RPPA): Functional proteomic profiling in leukemia. J Proteomics. 2020:104046.
2023
Bhutada I, Khambati F, Cheng S-Y, Tiek DM, Duckett D, Lawrence H, Vogelbaum MA, Mo Q, Chellappan SP, Padmanabhan J. CDK7 and CDK9 inhibition interferes with transcription, translation and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity. Neuro Oncol. 2023.
Rose A, Zhang L, Jain AG, Babu APoovathuka, Sokol L, Saeed H, Mo Q, Fan W, Zhang X. Delineation of Clinical Course, Outcomes, and Prognostic Factors in Patients with T-cell Prolymphocytic Leukemia. Am J Hematol. 2023.